• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Methodology for conducting a comprehensive product review in managed care.在托管式医疗中进行全面产品审查的方法。
J Manag Care Spec Pharm. 2023 Mar;29(3):237-243. doi: 10.18553/jmcp.2023.29.3.237.
2
Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs.支付治疗费用:我们如何负担得起? 探讨解决处方药可负担性问题的政策选择对管理式医疗保健药房利益相关者的影响
J Manag Care Spec Pharm. 2017 Oct;23(10):1084-1090. doi: 10.18553/jmcp.2017.23.10.1084.
3
AMCP Partnership Forum: Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval.AMCP 合作论坛:在 FDA 批准前实现临床和经济信息的交流。
J Manag Care Spec Pharm. 2017 Jan;23(1):105-112. doi: 10.18553/jmcp.2016.16366. Epub 2016 Dec 22.
4
The Current Status of Outcomes-Based Contracting for Manufacturers and Payers: An AMCP Membership Survey.基于结果的制造商和支付者合同的现状:AMCP 会员调查。
J Manag Care Spec Pharm. 2018 May;24(5):410-415. doi: 10.18553/jmcp.2017.16326. Epub 2017 Dec 22.
5
ESHRE guideline: endometriosis.ESHRE 指南:子宫内膜异位症。
Hum Reprod Open. 2022 Feb 26;2022(2):hoac009. doi: 10.1093/hropen/hoac009. eCollection 2022.
6
AMCP Partnership Forum: FDAMA Section 114-Improving the Exchange of Health Care Economic Data.AMCP 合作论坛:FDAMA 第 114 节——改善医疗保健经济数据的交流。
J Manag Care Spec Pharm. 2016 Jul;22(7):826-31. doi: 10.18553/jmcp.2016.22.7.826.
7
Advancing a managed care pharmacy research agenda: Generating real-world evidence to support US Food and Drug Administration Accelerated Approvals and improving benefit design to address health inequities.推进管理式医疗药学研究议程:生成真实世界证据以支持美国食品和药物管理局的加速审批,并改善受益设计以解决健康不平等问题。
J Manag Care Spec Pharm. 2022 Aug;28(8):911-917. doi: 10.18553/jmcp.2022.22049. Epub 2022 Jun 18.
8
AMCP Partnership Forum: The evolving role of digital therapeutics.AMCP 合作论坛:数字疗法的不断演变的角色。
J Manag Care Spec Pharm. 2022 Jul;28(7):804-810. doi: 10.18553/jmcp.2022.22093. Epub 2022 Jun 14.
9
Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.双相抑郁的治疗抵抗和多疗法抵抗标准:共识定义。
Br J Psychiatry. 2019 Jan;214(1):27-35. doi: 10.1192/bjp.2018.257. Epub 2018 Dec 6.
10
Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers.关于管理式医疗药房档案提交指南的意见:对管理式医疗组织和制药商的一项小型调查结果
J Manag Care Pharm. 2007 May;13(4):360-71. doi: 10.18553/jmcp.2007.13.4.360.

引用本文的文献

1
Advancing the conversation: 30 years of scholarship in managed care pharmacy.推动对话:管理式医疗药学30年学术研究
J Manag Care Spec Pharm. 2025 Jul;31(7):617-626. doi: 10.18553/jmcp.2025.31.7.617.
2
Pathways for non-manufacturers to drive generic drug repurposing for cancer in the U.S.美国非制药企业推动癌症通用药物重新利用的途径
Front Pharmacol. 2024 Oct 9;15:1419772. doi: 10.3389/fphar.2024.1419772. eCollection 2024.
3
A primer on brand-name prescription drug contracting.品牌处方药合同入门指南。
J Manag Care Spec Pharm. 2024 May;30(5):507-513. doi: 10.18553/jmcp.2024.24035. Epub 2024 Apr 23.
4
A primer on formulary structures and strategies.药物处方集结构和策略基础指南。
J Manag Care Spec Pharm. 2024 Feb 3;30(2):206-210. doi: 10.18553/jmcp.2024.30.2.206.
5
A primer on managed care pharmacy.管理式医疗药学概论。
J Manag Care Spec Pharm. 2023 Dec;29(12):1371-1376. doi: 10.18553/jmcp.2023.29.12.1371.

本文引用的文献

1
AMCP Partnership Forum: Principles for Sound Pharmacy and Therapeutics (P&T) Committee Practices: What's Next?AMCP 合作论坛:合理的药学和治疗学(P&T)委员会实践原则:下一步是什么?
J Manag Care Spec Pharm. 2020 Jan;26(1):48-53. doi: 10.18553/jmcp.2020.26.1.48.
2
Making health care safer II: an updated critical analysis of the evidence for patient safety practices.《提升医疗保健安全性II:对患者安全实践证据的最新批判性分析》
Evid Rep Technol Assess (Full Rep). 2013 Mar(211):1-945.
3
Deciding which drugs get onto the formulary: a value-based approach.确定纳入处方集的药物:基于价值的方法。
Value Health. 2013 Jul-Aug;16(5):901-6. doi: 10.1016/j.jval.2013.03.1623. Epub 2013 May 15.
4
Characteristics of published comparative effectiveness studies of medications.已发表的药物比较疗效研究的特征。
JAMA. 2010 Mar 10;303(10):951-8. doi: 10.1001/jama.2010.240.
5
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.预算影响分析良好实践原则:ISPOR良好研究实践特别工作组——预算影响分析报告
Value Health. 2007 Sep-Oct;10(5):336-47. doi: 10.1111/j.1524-4733.2007.00187.x.
6
Determination of the clinical importance of study results.研究结果临床重要性的判定
J Gen Intern Med. 2002 Jun;17(6):469-76. doi: 10.1046/j.1525-1497.2002.11111.x.
7
Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated?医疗保健研究与质量局临床实践指南的有效性:指南过时的速度有多快?
JAMA. 2001 Sep 26;286(12):1461-7. doi: 10.1001/jama.286.12.1461.

在托管式医疗中进行全面产品审查的方法。

Methodology for conducting a comprehensive product review in managed care.

机构信息

Xcenda, LLC, Carrollton, TX.

SelectHealth, Murray, UT.

出版信息

J Manag Care Spec Pharm. 2023 Mar;29(3):237-243. doi: 10.18553/jmcp.2023.29.3.237.

DOI:10.18553/jmcp.2023.29.3.237
PMID:36840955
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10388012/
Abstract

The high degree of complexity of the product-review process and differences in procedures between organizations have resulted in a need for best practices and an overall product-review process to create efficiencies for health care decision makers. In an effort to streamline product-review concepts, this article outlines the different components of the review process, including clinical and economic review, formulary placement determination, and evaluation of alternatives within a drug class. The article also details opportunities for the near future, as technology continues to advance and alignment between medical and pharmacy benefits is desired. Drs Linnerooth, Penley, Ha, and Craven report employment with Xcenda, which provided funding for the manuscript. Drs Sauvageau and Hydery report employment Xcenda, which provided funding for the manuscript, and stock holdings with AmerisourceBergen. Dr Feeney reports support for attending meetings and/or travel provided by Highmark, Inc. Dr Thomas reports receipt of consulting fees from ActiveRADAR, board member roles with ActiveRADAR and RoundtableRx, an adjunct professor role with the University of Minnesota, and stock options and pensions with Eli Lilly and Aetna/CVS. Dr Watkins reports payment or honoraria from ISPOR and for articles written for Value and Outcomes Spotlight, and support for attending meetings and/or travel by AMCP.

摘要

产品审查流程的高度复杂性以及组织之间程序的差异,导致需要采用最佳实践和全面的产品审查流程,为医疗保健决策者创造效率。为了简化产品审查概念,本文概述了审查流程的不同组成部分,包括临床和经济审查、定价目录位置确定以及药物类别内替代方案的评估。本文还详细介绍了未来的机会,因为技术不断进步,并且希望在医疗和药房福利之间实现一致。Linnerooth 博士、Penley 博士、Ha 博士和 Craven 博士报告受雇于 Xcenda,该公司为本文提供了资金。Sauvageau 博士和 Hydery 博士报告受雇于 Xcenda,该公司为本文提供了资金,并持有 AmerisourceBergen 的股票。Feeney 博士报告称,他参加会议和/或旅行的费用由 Highmark,Inc. 提供。Thomas 博士报告称,他从 ActiveRADAR 获得咨询费,担任 ActiveRADAR 和 RoundtableRx 的董事会成员,在明尼苏达大学担任兼职教授,以及从 Eli Lilly 和 Aetna/CVS 获得股票期权和养老金。Watkins 博士报告称,他从 ISPOR 获得报酬或酬金,并为 Value 和 Outcomes Spotlight 撰写文章,并由 AMCP 支付参加会议和/或旅行的费用。